Guillain-Barré Syndrome Following the mRNA COVID-19 Vaccination: Comment

Rujittika Mungmunpuntipantip[1]; Viroj Wiwanitkit[2]

Acta Neurol Taiwan 2023;32:228-229

Dear Editor, we would like to share ideas on the publication "Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine [1]." In order to advance our understanding of this consequence, Algahtani et al. describe a case of Guillain-Barré syndrome following the first dose of the BNT162b2 mRNA COVID-19 vaccination [1]. Guillain-Barré syndrome following COVID-19 vaccination is treatable, according to Algahtani et al. [1]. The advantages of providing the vaccination exceed the dangers, according to Algahtani et al. [1]. Algahtani and co. mentioned Given the detrimental effects of COVID-19, it is crucial to be aware of the emergence of any potential neurological side effects after immunization, such as Guillain-Barré syndrome [1].

We can all agree that COVID-19 prevention is essential and that additional research is required to address the underlying clinical problem. The outcome of a vaccination test and the development of a clinical condition may be related. Prior to treating the clinical issues caused by COVID-19 vaccination, a few crucial aspects need to be taken into account Comorbidities should be taken into account first. For instance, when the sickness and the clinical state co-occur, dengue vaccinations may be employed. Early detection of asymptomatic COVID-19 individuals is crucial [2]. It's likely that prior COVID-19 epidemics affected the effectiveness and outcomes of the immunization. Infection with COVID-19 may have an impact on clinical outcomes.

Without the necessary laboratory testing, it can be difficult to completely rule out an illness that was previously asymptomatic. A significant auxiliary influence is genetics [3]. The immune system's reaction to specific hereditary features may have an impact on how it reacts to the negative side effects of vaccination. Understanding how underlying genetic variables affect vaccine efficacy in clinical settings would be highly beneficial. In fact, more research is required to find a solution to this problem. The volume of clinical information needed will aid in researchers' knowledge.

Conflict of interest

None

From the [1]Private Academic Consultant, Bangkok Thailand; [2]Adjunct professor, Chandigarh University, Punjab, India; Adjunct professor, Joesph Ayobabalola University, Ikeji-Arakeji, Nigeria

Received May 22, 2023. Revised May 31, 2023.
Accepted May 31, 2023.

Correspondence to: Rujittika Mungmunpuntipantip
Private Academic Consultant, Bangkok Thailand
Email: rujittika@gmail.com

REFERENCE

1. Algahtani HA, Shirah BH, Albeladi YK, Albeladi RK. Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine. Acta Neurol Taiwan. 2023 Jun 30;32(2):82-85.
2. Joob B, Wiwanitkit V. Letter to the Editor: Coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period. J Prev Med Public Health. 2020 Mar;53(2):70
3. Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022 Aug 29;13:932043.